SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 6

Synthetic peptide vaccine for Foot-and- Mouth Disease: synthesis, characterization and immunogenicity

Kadriye KIZILBEY
Sezen Canım ATEŞ
Zeynep MUSTAFAEVA AKDESTE
Serap DERMAN
Banu MANSUROĞU
Pages
859–868
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Peptide formulated in the conjugated form hadhigher antibody response than free peptide and control(p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The conjugations of antigenic syntheticpeptide sequences with carrier polymers have opened newpossibilities for the treatment of diseases.
📊
Key Findings & Data:In this study,135–161 peptide sequence of VP1 capsid protein of Footand-Mouth Disease was cross-linked with P(VP-co-AA)copolymer by covalent conjugation using water-solublecarbodiimide at different ratio of components (γ=5, 7, 9, 11,15) for the first time in the literature.Materials and methods: Bioconjugates were characterizedby gel permeation chromatography and fluorescence spectroscopyto identify occurrences of the conjugates.
💡
Conclusion & Impact:Peptide formulated in the conjugated form hadhigher antibody response than free peptide and control(p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: The conjugations of antigenic syntheticpeptide sequences with carrier polymers have opened newpossibilities for the treatment of diseases. In this study,135–161 peptide sequence of VP1 capsid protein of Footand-Mouth Disease was cross-linked with P(VP-co-AA)copolymer by covalent conjugation using water-solublecarbodiimide at different ratio of components (γ=5, 7, 9, 11,15) for the first time in the literature.Materials and methods: Bioconjugates were characterizedby gel permeation chromatography and fluorescence spectroscopyto identify occurrences of the conjugates. After characterization,γ=15 bioconjugate was determined as optimumconjugate for immunization studies and IC50 value is calculatedas 1.227 mg/mL. By determining the nontoxic range, indirectELISA were performed to evaluate the immune response elicitedin balb/c mice by either peptide or P(VP-co-AA)-peptidebioconjugates (γ=15). Two injections were applied to eachgroup and high immune responses were obtained against γ=15conjugate compared to free peptide and control.Results and conclusion: At the end of 9-week, the generalpattern of immunoreactivity was acquired as γ=15>>peptide>control. Peptide formulated in the conjugated form hadhigher antibody response than free peptide and control(p

Özet

Amaç: Antijenik özellikli sentetik peptit dizilerinin taşıyıcı polimerler ile konjugasyonu, hastalıkların tedavisi için yeni olanaklar yaratmaktadır. Bu çalışmada literatürde ilk kez, Ayak ve Ağız Hastalığının VP1 kapsid proteininin 135–161 peptit dizisi, farklı bileşen oranlarında suda çözünür karbodiimid kullanılarak P(VP-ko-AA) kopolimeriyle kovalent konjugasyon ile çapraz bağlanmıştır (γ=5, 7, 9, 11, 15). Gereç ve Yöntem: Biyokonjugatlar, konjugatların oluşumlarını tanımlamak için jel geçirgenlik kromatografisi ve floresan spektroskopisi ile karakterize edilmiştir. Karakterizasyondan sonra γ=15 biyokonjugatı immünizasyon çalışmaları için optimum konjugat olarak belirlenmiş ve IC50 değeri 1.227 mg/ml olarak hesaplanmıştır. Toksik olmayan aralığın belirlenmesiyle, balb/c farelerinde peptit veya P(VP-ko-AA)- peptid biyokonjugatlarına karşı oluşan immün cevabı değerlendirmek için dolaylı ELISA yapılmıştır (γ=15). Her gruba iki enjeksiyon uygulanmış ve serbest peptit ve kontrole kıyasla γ=15 konjugatına karşı yüksek immün yanıt elde edilmiştir. Bulgular ve Sonuç: 9 haftanın sonunda, immün reaktivitenin genel örüntüsü γ=15>peptid>kontrol şeklinde elde edilmiştir. Konjüge formda formüle edilmiş peptit, serbest peptit ve kontrolden daha yüksek antikor cevabı oluşturmuş (her iki durumda da p

🔖

Cite This Article

KIZILBEY, K., ATEŞ, S. C., AKDESTE, Z. M., DERMAN, S., MANSUROĞU, B. (2022). Synthetic peptide vaccine for Foot-and- Mouth Disease: synthesis, characterization and immunogenicity. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 6, 859–868. https://ajindex.com/articles/620813

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Arnon R, Maron E, Sela M, Anfinsen CB. Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci 1971;68:1450–5
  2. Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 2002;20:2603–10
  3. Beignon AS, Brown F, Eftekhari P, Kramer E, Briand JP, Muller S, et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol Immunopathol 2005;104:273–80
  4. Gladue DP, O’Donnell V, Baker-Branstetter R, Holinka LG, Pacheco JM, Fernández Sainz I, et al. Foot-and-mouth disease virus modulates cellular vimentin for virus survival. J Virol 2013;87:6794–803
  5. Meloen RH, Langeveld JP, Schaaper WM, Slootstra JW. Synthetic peptide vaccines: unexpected fulfillment of discarded hope?. Biologicals 2001;29:233–6
  6. Cubillos C, Torre BG, Jakab A, Clementi G, Borrás E, Bárcena J, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. J Virol 2008;82: 7223–30
  7. Xue B, Blocquel D, Habchi J, Uversky AV, Kurgan L, Uversky VN, et al. Do viral proteins possess unique features? In: Uversky VN and Longhi S, editors. Flexible viruses: structural disorder in viral proteins. Hoboken, NJ: Wiley; 2012:1–34
  8. Taboga O, Tami C, Carrillo E, Núñez JI, Rodríguez A, Saíz JC, et al. A large-scale evaluation of peptide vaccines against foot-andmouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 1997;71:2606–14
  9. Strohmaier K, Franze RT, Adam KH. Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol 1982;59:295–306
  10. Francis MJ, Hastings GZ, Clarke BE, Brown AL, Beddell CR, Rowlands DJ, et al. Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides. Immunology 1990;69:171
  11. Geysen HM, Rodda SJ, Mason TJ. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol 1986;23:709–15
  12. Beck E, Strohmaier K. Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol 1987;61:1621–9
  13. Nandedkar TD. Nanovaccines: recent developments in vaccination. J Biosci 2009;34:995–1003
  14. Barclay T, Petrovsky N. Vaccine adjuvant nanotechnologies. In: Skwarczy